[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adenoid-cystic-carcinoma-of-the-salivary-gland\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adenoid-cystic-carcinoma-of-the-salivary-gland":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100631968","a-multi-omics-approach-to-disclose-progression-and-underlying-biology-of-head-and-neck-adenoid-cystic-carcinoma-100631968",false,"NCT07507578","A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma","A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma (MAPPING-ACC)","MAPPING-ACC","Inclusion Criteria:\n\n* Pathologic diagnosis of ACC\n* Primary ACC arising from the head and neck\n* Unequivocal clinical and\u002For radiological evidence of metastatic disease\n* Patient ability and availability to comply with study protocol procedures.\n\nExclusion Criteria:\n\n* ACC patients with local and\u002For regional recurrence without distant metastases\n* Primary ACC arising from any non-head and neck region (e.g., breast, lung, skin etc)\n* Insufficient data about previous medical history.","ALL","18 Years",{"count":20,"type":21},114,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to better understand why some people with metastatic adenoid cystic carcinoma (ACC) of the head and neck have slow-growing disease while others have faster-growing or more aggressive disease. Researchers want to learn how the biology of the tumor relates to each person's clinical risk group, which is based on a published prediction tool (a nomogram).\n\nThe main question the study aims to answer is: Do people in the high-risk and low-risk groups have different biological tumor types (called ACC-I and ACC-II) when their primary tumor is tested?\n\nThe study will also look at other important questions, such as:\n\n* Do metastatic tumors show the same biological type as the original tumor?\n* Do biological types differ based on where metastases grow or how early or late they appear?\n* Are biological types linked to how well systemic treatments work?\n* Can blood tests (including DNA fragments or small RNA molecules in the blood) show the same tumor biology and help track how the cancer changes over time?\n\nParticipants will:\n\n* Allow researchers to study samples of tumor tissue taken in the past during standard care.\n* Give blood samples at study entry and then every 6 months for up to 2 years.\n* Continue all medical treatments and follow-up visits as decided by their own care team.\n* Receive no study treatment; this study only collects information and samples.\n\nAbout 114 adults with metastatic ACC of the head and neck will join the study. People with only local or regional recurrence (without metastases) or those whose primary tumor started outside the head and neck cannot take part.\n\nThe information gathered may help researchers understand why ACC behaves differently from person to person, identify new biological markers in blood, and support future personalized treatment strategies for people with metastatic ACC.",[25,26],"Adenoid Cystic Carcinoma of the Salivary Gland","Adenoid Cystic Carcinoma of the Head and Neck","RECRUITING","2026-03-27",{"date":30,"type":31},"2026-04-02","ACTUAL",{"date":33,"type":31},"2025-03-01",{"date":35,"type":21},"2028-12-31",{"name":37,"class":38},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":5},"100481804","early-phase-1-drug-screening-using-novel-imd-in-salivary-and-head-and-neck-cancers-100481804","NCT05553782","Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers","Therapeutic Drug Screening Using a Novel Implantable Microdevice (IMD) in Head and Neck Cancers: a Window of Opportunity Study","Inclusion Criteria:\n\n* Participants must have histologically confirmed head and neck cancer (salivary or ACC type, or squamous cell carcinoma) without evidence of recurrent, metastatic or advanced, incurable disease undergoing definitive surgical management; any stage disease is permitted (American Joint Committee on Cancer 2017 8th edition).\n* Age 18 years or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* A measurable primary tumor site both clinically and radiologically measuring at least 1 x 1 cm.\n\n  \\- Patients must be deemed medically fit to undergo both percutaneous and surgical procedures by their treating head and neck surgeon and medical oncologist.\n* Participants will undergo laboratory testing within 7 days prior to the microdevice placement: they are required to have a platelet count ≥50,000\u002FmcL, PT\u002FINR \\\u003C2, and aPTT \\\u003C1.5x upper limit of normal.\n* Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 14 days\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who are receiving any other investigational agents.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit the safety of a biopsy and\u002For surgery.\n* Pregnant women are excluded from this study because of the possible increased dose of radiation from imaging associated with the device placement and the potential risk to the pregnancy of the surgery\u002Fdevice placement.\n* Uncorrectable bleeding or coagulation disorder known to cause increased risk with surgical or percutaneous biopsy procedures. If the patient is on systemic anticoagulation, this should be discussed with the overall PI and treating surgeon",{"count":48,"type":21},30,"INTERVENTIONAL",[51],"EARLY_PHASE1","This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers\u002F\n\nThe name of the study intervention involved in this study is:\n\n\\-- implantable microdevice",[54,25,55,56],"Salivary Gland Cancer","Squamous Cell Carcinoma of Head and Neck","Head and Neck Cancer",[54,25,58,55],"Implantable Microdevice IMD","2026-01-23",{"date":61,"type":31},"2026-01-26",{"date":63,"type":31},"2023-11-01",{"date":65,"type":21},"2029-08-01",{"name":67,"class":38},"Brigham and Women's Hospital"]